Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study.Published in
BMC Public Health 2021; 21(1):1752PMID
34565374ae974a485f413a2113503eed53cd6c53
10.1186/s12889-021-11767-9
Scopus Count
Collections
Related articles
- Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
- Authors: Quiambao BP, Jain H, Bavdekar A, Dubey AP, Kolhe D, Bianco V, Van der Wielen M, Miller JM
- Issue date: 2016 Aug 2
- Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
- Authors: van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM
- Issue date: 2017 Aug 24
- Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
- Authors: Borja-Tabora CF, Montalban C, Memish ZA, Boutriau D, Kolhe D, Miller JM, Van der Wielen M
- Issue date: 2015 Oct 6
- Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
- Authors: Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM
- Issue date: 2015 Dec
- Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers.
- Authors: Bona G, Castiglia P, Zoppi G, de Martino M, Tasciotti A, D'Agostino D, Han L, Smolenov I
- Issue date: 2016 Jun 17